Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors

Summary The establishment of robust HCV cell culture systems and characterization of the viral life cycle provided the molecular basis for highly innovative, successful years in HCV drug development. With the identification of direct-acting antiviral agents (DAAs), such as NS3/4A protease inhibitors...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2014-11, Vol.61 (1), p.S98-S107
Hauptverfasser:	Welzel, Tania Mara, Dultz, Georg, Zeuzem, Stefan
Format:	Artikel
Sprache:	eng
Schlagworte:	All oral Antiviral Agents - therapeutic use Direct-acting antiviral agents (DAAs) Drug Therapy, Combination Gastroenterology and Hepatology Genotype Hepacivirus - genetics Hepatitis C - drug therapy Host-targeting agents (HTAs) Humans Interferon-free HCV treatment Interferons - therapeutic use Non-nucleoside polymerase inhibitors (NNI) NS3/4A protease inhibitors (PI) NS5A inhibitors Nucleic Acid Synthesis Inhibitors - therapeutic use Oligopeptides - therapeutic use Proline - analogs & derivatives Proline - therapeutic use Protease Inhibitors - therapeutic use Viral Nonstructural Proteins - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!